Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Semapimod. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK4 | O00444 | 1/20 | 0.63 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.63 |
| ▸ | AURKA | O14965 | 1/20 | 0.63 |
| ▸ | CHUK | O15111 | 1/20 | 0.63 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.63 |
| ▸ | JAK2 | O60674 | 1/20 | 0.63 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.63 |
| ▸ | PAK4 | O96013 | 1/20 | 0.63 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.63 |
| ▸ | CDK1 | P06493 | 1/20 | 0.63 |
| ▸ | PIM1 | P11309 | 1/20 | 0.63 |
| ▸ | PRKACA | P17612 | 1/20 | 0.63 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.63 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.63 |
| ▸ | CDK2 | P24941 | 1/20 | 0.63 |
| ▸ | MARK3 | P27448 | 1/20 | 0.63 |
| ▸ | AKT1 | P31749 | 1/20 | 0.63 |
| ▸ | AKT2 | P31751 | 1/20 | 0.63 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.63 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11989635 | 1.00 | PLK4 (0.63) | PLK4CHEK1AURKACHUKDAPK3 | |
| Semapimod SCHEMBL12201344 | 1.00 | PLK4 (0.63) | PLK4CHEK1AURKACHUKDAPK3 | |
| Semapimod SCHEMBL6356573 | 0.99 | PLK4 (0.62) | PLK4CHEK1AURKACHUKDAPK3 | |
| Semapimod SCHEMBL6356576 | 0.99 | PLK4 (0.62) | PLK4CHEK1AURKACHUKDAPK3 | |
| SCHEMBL11989623 | 0.99 | PLK4 (0.64) | PLK4CHEK1AURKACHUKDAPK3 | |
| SCHEMBL11989630 | 0.96 | PLK4 (0.59) | PLK4CHEK1AURKACHUKDAPK3 | |
| SCHEMBL11989628 | 0.96 | PLK4 (0.59) | PLK4CHEK1AURKACHUKDAPK3 | |
| SCHEMBL13248987 | 0.96 | PLK4 (0.59) | PLK4CHEK1AURKACHUKDAPK3 | |
| SCHEMBL24681759 | 0.95 | PLK4 (0.58) | PLK4CHEK1AURKACHUKDAPK3 | |
| SCHEMBL16207216 | 0.95 | PLK4 (0.58) | PLK4CHEK1AURKACHUKDAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3069732-B1 | DRUG FOR TREATING CORNEAL ENDOTHELIUM BY PROMOTING CELL PROLIFERATION OR INHIBITING CELL DAMAGE | THE DOSHISHA (JP) | 2023-07-12 | — | — | EP | claimed |
| WO-2023285654-A2 | COMPOUNDS FOR THE TREATMENT OF COVID-19 | DOMPE' FARMACEUTICI SPA (IT) | 2023-01-19 | — | — | WO | claimed |
| EP-3553169-B1 | NORMALIZATION OF CULTURE OF CORNEAL ENDOTHELIAL CELLS | KYOTO PREFECTURAL PUBLIC UNIV CORP (JP) | 2021-11-03 | — | — | EP | claimed |
| US-20160331736-A1 | DRUG FOR TREATING CORNEAL ENDOTHELIUM BY PROMOTING CELL PROLIFERATION OR INHIBITING CELL DAMAGE | THE DOSHISHA (JP) | 2016-11-17 | — | — | US | claimed |
| EP-3069732-A1 | DRUG FOR TREATING CORNEAL ENDOTHELIUM BY PROMOTING CELL PROLIFERATION OR INHIBITING CELL DAMAGE | The Doshisha (JP) | 2016-09-21 | — | — | EP | claimed |
| US-20250302883-A1 | NORMALIZATION OF CULTURE OF CORNEAL ENDOTHELIAL CELLS | KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (JP) | 2025-10-02 | — | — | US | disclosed |
| EP-3069732-B1 | DRUG FOR TREATING CORNEAL ENDOTHELIUM BY PROMOTING CELL PROLIFERATION OR INHIBITING CELL DAMAGE | THE DOSHISHA (JP) | 2023-07-12 | — | — | EP | disclosed |
| US-20230057984-A1 | NORMALIZATION OF CULTURE OF CORNEAL ENDOTHELIAL CELLS | KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (JP) | 2023-02-23 | — | — | US | disclosed |
| US-10980787-B2 | Drug for treating or preventing disorder caused by TGF-B signals, and application thereof | THE DOSHISHA (JP) | 2021-04-20 | — | — | US | disclosed |
| US-10813920-B2 | Drug for treating corneal endothelium by promoting cell proliferation or inhibiting cell damage | THE DOSHISHA (JP) | 2020-10-27 | — | — | US | disclosed |
| US-20180369220-A1 | DRUG FOR TREATING OR PREVENTING DISORDER CAUSED BY TGF-B SIGNALS, AND APPLICATION THEREOF | THE DOSHISHA (JP) | 2018-12-27 | — | — | US | disclosed |
| EP-3381472-A1 | DRUG FOR TREATING OR PREVENTING DISORDER CAUSED BY TGF- SIGNALS, AND APPLICATION THEREOF | The Doshisha (JP) | 2018-10-03 | — | — | EP | disclosed |
| EP-3069732-A1 | DRUG FOR TREATING CORNEAL ENDOTHELIUM BY PROMOTING CELL PROLIFERATION OR INHIBITING CELL DAMAGE | The Doshisha (JP) | 2016-09-21 | — | — | EP | disclosed |
| US-20150044178-A1 | NORMALIZATION OF CULTURE OF CORNEAL ENDOTHELIAL CELLS | KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (JP) | 2015-02-12 | — | — | US | disclosed |
| EP-2799537-A1 | NORMALIZATION OF CULTURE OF CORNEAL ENDOTHELIAL CELLS | Kyoto Prefectural Public University Corporation (JP) | 2014-11-05 | — | — | EP | disclosed |
| EP-1255541-B1 | AROMATIC GUANYLHYDRAZONE FOR THE TREATMENT OF RESISTANT VIRAL INFECTIONS | BEVEC DORIAN (DE) | 2005-11-09 | — | — | EP | disclosed |
| US-20050171176-A1 | Pharmaceutically active aromatic guanylhydrazones | BEVEC DORIAN (DE) | 2005-08-04 | — | — | US | disclosed |
| US-20030203969-A1 | Pharmaceutically active aromatic guanylhydrazones | AXXIMA PHARMACEUTICALS AG (DE) | 2003-10-30 | — | — | US | disclosed |
| EP-1255541-A2 | PHARMACEUTICALLY ACTIVE AROMATIC GUANYLHYDRAZONES | Axxima Pharmaceuticals Aktiengesellschaft (DE) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001056553-A2 | PHARMACEUTICALLY ACTIVE AROMATIC GUANYLHYDRAZONES | AXXIMA PHARMACEUTICALS AG (DE) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203969-A1 | Pharmaceutically active aromatic guanylhydrazones | DHPS, GGPS1, GMPS | PLK4 3273/4885CHEK1 4752/4885AURKA 1623/4885 |
| US-20050171176-A1 | Pharmaceutically active aromatic guanylhydrazones | DHPS, GGPS1, GMPS | PLK4 3261/4885CHEK1 4743/4885AURKA 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.